Strategically, Biocon will be one of the few companies offering both biosimilars and generics at a global scale. As the only company with biosimilar insulins and generic GLP1 peptides, Biocon is uniquely …

Biocon is addressing global medical needs through a portfolio of differentiated and high quality, life saving biotherapeutics.

At Biocon, we pioneer novel approaches to improve patient outcomes today, for a better tomorrow. We constantly find new ways to treat diabetes, cancer and autoimmune diseases to improve the quality …

Jul 17, 2020 · Biocon is an innovation led fully integrated biopharmaceutical company that has developed affordable biosimilars, novel biologics and complex APIs. Leader in fermentation based …

Biocon Limited is a globally recognized, innovation-led organization that is enabling access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet …

Apr 10, 2025 · Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives.

Jan 6, 2026 · Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, …

5 days ago · Access Biocon's latest & archived press releases, intended information for business journalists, News & Social Media, Analysts & Investors...

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon …

Biocon has one of the largest global biosimilars portfolios, spanning recombinant human Insulin (rh-Insulin), insulin analogs, monoclonal antibodies and other biologics for diabetes, oncology and …